Novartis | NOVN - Loan Capital


Novartis reported $37.49B in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Alcon AG USD 4.16B 434M Mar/2026
Almirall EUR 303.77M 21.04M Jun/2026
Amgen USD 51.86B 27M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
Autolus Therapeutics Ltd USD 277.27M 7.07M Mar/2026
Bayer EUR 30.68B 1.15B Mar/2026
Biogen USD 7.29B 1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Fresenius EUR 9.55B 1.24B Jun/2026
Fresenius Medical Care EUR 5.74B 895.27M Mar/2026
Genmab DKK 4.96B 28M Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
GRIFOLS EUR 7.17B 1.91B Jun/2026
Hikma Pharmaceutical USD 1.49B 692M Dec/2025
J&J USD 37.34B 183M Jun/2026
Lakefront Biotherapeutics EUR 4.85M 335K Mar/2026
Lonza CHF 3.88B 323M Dec/2025
Merck EUR 10.8B 72M Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Novartis USD 37.49B 42M Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Novo Nordisk DKK 121.79B 2.62B Jun/2026
Orion EUR 103.4M 7.2M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
Philips EUR 6.32B 575M Jun/2026
Recordati EUR 1.69B 67.09M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
UCB EUR 2.18B 634M Dec/2025